Diffuse large B-cell lymphoma trials in United States

In United States 131 Also abroad 347

120 of 131 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Albany, Alexandria, Ann Arbor, Athens, Belleville, Bethesda, Billings, Bridgeton, Charlottesville, Cincinnati, Clermont, Columbia, Dallas, Detroit, Eugene, Fargo, Fort Wayne, Fullerton, Gilbert, Golden, Grand Rapids, Greenville, Hampton, Hialeah, Hinsdale, Houston, Jackson, Kansas City, Knoxville, Las Vegas, Lexington, Long Beach, Los Alamitos, Los Angeles, Louisville, Lubbock, Madison, Mobile, Naperville, Nashville, New York, Ocoee, O'Fallon, Olympia, Orange City, Owensboro, Phoenix, Portland, Reno, Richmond, Roanoke, Saginaw, San Francisco, Shirley, Sioux Falls, Springfield, Tampa, The Woodlands, Topeka, Tucson
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 2Taking people
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Where
Albany, Anchorage, Aurora, Baton Rouge, Boise, Boston, Chattanooga, Clovis, East Syracuse, Eugene, Fairfax, Fullerton, Gainesville, Glendale, Grand Rapids, Lexington, Los Angeles, Miami, Nashville, Omaha, Orlando, Panorama City, Portland, San Francisco, Swansea, Tacoma, Temple, The Woodlands, Torrance, Tyler, Virginia Beach, Waukee
Age
18 years and over
People
130 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06806033 · EU 2024-516791-15-00
Phase 1/2Taking people
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
Where
Irvine, Nashville
Age
18 years and over
People
274
Run by
Umoja Biopharma
See details and how to joinNCT07735533
Phase 1/2Taking people
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Where
Bethesda
Age
18 years to 120 years
People
155
Run by
National Cancer Institute (NCI)
See details and how to joinNCT03223610
Phase 2Taking people
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Where
Bethesda
Age
18 years and over
People
132
Run by
National Cancer Institute (NCI)
See details and how to joinNCT04002947
Phase 2Taking people
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
Where
Ames, Anaconda, Ankeny, Ashland, Bellevue, Bethesda, Billings, Boone, Bozeman, Brainerd, Buffalo, Burlington, Canton, Carroll, Cedar Rapids, Charlottesville, Chicago, Cincinnati, City of Saint Peters, Cleveland, Clive, Coeur d'Alene, Columbus, Creve Coeur, Crown Point, Danville, Deer River, DeKalb, Derby, Des Moines, Duluth, Durham, Dyer, Effingham, Escanaba, Fargo, Fort Dodge, Geneva, Glenview, Grayslake, Great Falls, Green Bay, Guilford, Hibbing, Hobart, Hood River, Indianapolis, Janesville, Jefferson, Kalispell, La Crosse, Lake Forest, Los Angeles, Madison, Manistique, Marshalltown, Mattoon, Menomonee Falls, Milwaukee, Missoula, Mukwonago, Munster, Newberg, New Berlin, New Haven, New Orleans, Normal, Oak Brook, Oak Creek, Oconomowoc, Oconto Falls, Oklahoma City, Omaha, Oregon City, Orland Park, Philadelphia, Portland, Post Falls, Richmond, Sandpoint, Sandstone, Seattle, Sheboygan, Shiloh, Spooner, St Louis, Sturgeon Bay, Superior, Tucson, Urbana, Valparaiso, Virginia, Warrenville, Waukee, Waukesha, West Bend, West Chester
Age
18 years and over
People
120
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06649812
Phase 2Not yet taking people in United States
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
Where
Omaha
Age
19 years and over
People
50
Run by
University of Nebraska
See details and how to joinNCT07517705
Phase 2Not yet taking people in United States
The CARDIOPROTECT Trial
Where
Boston
Age
18 years and over
People
60
Run by
Beth Israel Deaconess Medical Center
See details and how to joinNCT07654426
Phase 1Taking people
AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")
Where
Rockville
Age
18 years and over
People
15
Run by
National Cancer Institute (NCI)
See details and how to joinNCT07649304
Phase 2Taking people
Auto Stem Cell Transplant for Lymphoma Patients
Where
Minneapolis
Age
Up to 75 years
People
150
Run by
Masonic Cancer Center, University of Minnesota
See details and how to joinNCT03125642
Phase 3Taking people
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Where
Baltimore, Boston, Cleveland, Detroit, Durham, Grand Rapids, Greenville, Houston, Indianapolis, Jacksonville, Lexington, Los Angeles, New Brunswick, Noblesville, Ogden, Orange, Rochester, Sacramento, Scottsdale, Stony Brook, Waukesha, Westbury
Age
18 years and over
People
904 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06091865 · EU 2022-502785-25-00
Phase 3Taking people
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
Where
Albuquerque, Atlanta, Aurora, Austin, Boston, Buffalo, Chicago, Cincinnati, Cleveland, Denver, Durham, Fort Worth, Gilbert, Hackensack, Houston, Iowa City, Jacksonville, Little Rock, Los Angeles, Louisville, Milwaukee, Morristown, Nashville, Norfolk, Omaha, Orange, Orlando, Pittsburgh, Richmond, Rochester, Salt Lake City, San Antonio, Scottsdale, Tampa, Washington D.C., Westwood, Winston-Salem
Age
18 years and over
People
400 worldwide
Run by
Lyell Immunopharma, Inc.
See details and how to joinNCT07188558
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Atlanta, Boston, Columbus, Dallas, Denver, Duarte, Houston, Los Angeles, Miami, Milwaukee, Nashville, New York, Portland, Rochester, San Francisco, Sarasota, Scottsdale, Seattle
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Baltimore, Beverly Hills, Billings, Boca Raton, Boston, Clermont, Edgewood, Glendale, Grand Island, Grand Rapids, Hialeah, Horsham, Knoxville, Las Vegas, Lexington, Louisville, Morristown, Nashville, Niles, Omaha, Rio Rancho, Roanoke, Valhalla, Walnut Creek, Whittier, Worcester
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 1Taking people
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
Where
Baltimore
Age
18 years and over
People
140 worldwide
Run by
Iksuda Therapeutics Ltd.
See details and how to joinNCT05365659
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Amarillo, Aurora, Austin, Baton Rouge, Boca Raton, Boston, Bozeman, Buffalo, Burbank, Burnsville, Chandler, Chapel Hill, Charleston, Charlotte, Chicago, Cincinnati, Cleveland, Dallas, Duarte, Edgewood, Elizabethtown, Glendale, Goodyear, Grand Junction, Hot Springs, Iowa City, Jacksonville, Knoxville, La Jolla, Lexington, Lincoln, Louisville, Madison, Manassas, Mayfield Heights, Miami Beach, Milwaukee, Mineola, Mobile, Monroe, Morristown, Murray, Nashville, Newark, New Orleans, New York, Omaha, Orange City, Palestine, Paramus, Peoria, Philadelphia, Portland, Post Falls, Richmond, San Antonio, Sellersville, Shreveport, St. George, Syracuse, Tyler, Vancouver, Walnut Creek, Washington D.C., Waukee, Westbury, Winston-Salem, York
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1Taking people
A Study of ARC-02 in B-cell NHL
Where
Charlotte, Los Angeles, Louisville, Milwaukee, Richmond, Spokane
Age
18 years and over
People
140 worldwide
Run by
Taiho Oncology, Inc.
See details and how to joinNCT07691606 · EU 2026-525606-35-00
Phase 2Taking people
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
Where
Beltsville, Berkeley, Des Moines, Detroit, Jacksonville, La Jolla, Lexington, Lubbock, Olympia, Orange, Sioux Falls, Stamford, Tacoma, Towson
Age
65 years to 99 years
People
80 worldwide
Run by
AstraZeneca
See details and how to joinNCT05952024
Phase 1/2Taking people
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Where
Aurora, Boston, Fargo, Grand Rapids, Houston, Iowa City, Kansas City, Los Angeles, New Brunswick, New Haven, New York, Philadelphia, Portland, Salt Lake City, Sioux Falls, St. Petersburg, Valhalla
Age
6 months to 25 years
People
90 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00
Phase 2Taking people
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Where
Atlanta, Augusta, Austin, Baltimore, Berkeley, Bethesda, Boston, Charlotte, Charlottesville, Chicago, Cincinnati, Cleveland, Columbia, Dallas, Duarte, Durham, East Brunswick, Eugene, Fairfax, Fort Wayne, Gilbert, Hackensack, Hot Springs, Houston, Indianapolis, Kansas City, Lexington, Lone Tree, Los Angeles, Louisville, Miami, Minneapolis, Nashville, Newark, New Brunswick, New York, Norfolk, Orlando, Philadelphia, Pittsburgh, Portland, Rochester, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, Seattle, Sioux Falls, Springfield, St Louis, Tampa, Tyler, Washington D.C.
Age
18 years and over
People
250 worldwide
Run by
Allogene Therapeutics
See details and how to joinNCT06500273
Phase 2Taking people
A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma
Where
Basking Ridge, Commack, Hackensack, Harrison, Middletown, Montvale, New York, Rockville Centre
Age
65 years to 80 years
People
42
Run by
Memorial Sloan Kettering Cancer Center
See details and how to joinNCT06765317
Early phase 1Taking people
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Where
Baltimore, Chapel Hill, Chicago, Columbus, Houston, Miami, New York, Philadelphia, Salt Lake City
Age
18 years and over
People
15
Run by
AIDS Malignancy Consortium
See details and how to joinNCT04139304
Phase 2Taking people
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Where
Ankeny, Ann Arbor, Appleton, Ashland, Beverly Hills, Brighton, Burlington, Canton, Cedar Rapids, Charleston, Chelsea, Chicago, City of Saint Peters, Clive, Creve Coeur, Crown Point, Danville, Deer River, Des Moines, Duarte, Duluth, Dyer, Eau Claire, Effingham, Flint, Fort Lauderdale, Germantown, Grafton, Green Bay, Hibbing, Hobart, Houston, Huntington Beach, Indianapolis, Jackson, Kenosha, La Crosse, Lancaster, Lansing, Livonia, Long Beach, Los Angeles, Marinette, Marshfield, Mattoon, Miami Beach, Milwaukee, Minocqua, Munster, Newberg, New Lenox, Newport Beach, New York, Oklahoma City, Oregon City, Orland Park, Oshkosh, Pontiac, Portland, Racine, Rice Lake, Richmond, Rochester, Salt Lake City, San Antonio, Sandstone, Sheboygan, Shiloh, South Pasadena, Stevens Point, St Louis, Summit, Torrance, Tucson, Two Rivers, Upland, Urbana, Valparaiso, Virginia, Wauwatosa, Webster, West Allis, Weston, Ypsilanti
Age
18 years and over
People
227
Run by
SWOG Cancer Research Network
See details and how to joinNCT05890352
Phase 1Taking people
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Where
San Francisco
Age
18 years and over
People
36
Run by
C. Babis Andreadis
See details and how to joinNCT04545762
Phase 1Taking people
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Charlottesville, Chicago, Cleveland, Duarte, Oklahoma City, Sacramento, Tampa, Winston-Salem
Age
18 years and over
People
30
Run by
National Cancer Institute (NCI)
See details and how to joinNCT06015880